FDA warning letters target marketers of unapproved weight loss drugs RAPS The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York FDA Warning Letter to Neil R. Feins, M.D. 2009 05 20 Circare NDI warning letters fuel criticism of FDA enforcement approach